Idexx Laboratories (IDXX) AI Stock Analysis

• Market Cap: $50.99B
• Dividend Yield: N/A
• Average Volume (3M): 411.21K
• Price to Earnings (P/E): 53.0
• Beta (1Y): 1.09
• Revenue Growth: 6.68%
• EPS Growth: 18.84%
• Country: US
• Employees: 11,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 3.63
• Shares Outstanding: 80,004,690
• 10 Day Avg. Volume: 376,840
• 30 Day Avg. Volume: 411,211
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.87
• Enterprise Value/Revenue: 11.02
• Enterprise Value/Gross Profit: 17.91
• Enterprise Value/Ebitda: 31.75
• 1Y Price Target: $723.89
• Price Target Upside: 13.58% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 10

• Rating: 73 Outperform
• Price Target: $713.00 ▲(11.87% Upside)

Idexx Laboratories' overall stock score is driven by strong financial performance and a positive earnings call, indicating robust growth prospects. However, high valuation and neutral technical indicators slightly temper the outlook. The company's strategic focus on international markets and innovation supports its long-term growth potential.

Positive Factors

Strong Revenue Growth

The company's robust revenue growth indicates strong market demand and effective business strategy, enhancing its competitive position and long-term growth potential.

Record Instrument Placements

Record instrument placements reflect successful product adoption and customer trust, which can drive recurring revenue and reinforce market leadership in diagnostics.

International Market Expansion

Strong international growth underscores IDEXX's ability to expand its global footprint, diversifying revenue streams and reducing reliance on domestic markets.

Negative Factors

Decline in U.S. Clinical Visits

A decline in U.S. clinical visits could impact domestic revenue growth, posing a challenge to maintaining overall revenue momentum if not addressed.

Challenges in Rapid Assay Revenues

Declining Rapid assay revenues suggest potential product transition challenges, which could affect short-term revenue from this segment if not managed effectively.

Low Equity Ratio

A low equity ratio may indicate financial instability risk, potentially limiting the company's ability to leverage future growth opportunities without increasing financial risk.

Idexx Laboratories Business Overview & Revenue Model

Company Description

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

How the Company Makes Money

IDEXX Laboratories generates revenue through multiple key streams, primarily focusing on its diagnostic products and services for the veterinary market. The Companion Animal Group represents the largest segment, contributing significantly to revenue through the sale of point-of-care diagnostic tests, laboratory services, and related software. The company also earns revenue from its Livestock, Poultry, and Dairy segment, which provides diagnostic solutions for animal health and food safety. Additionally, IDEXX's Water and Food Testing segment contributes to its earnings through advanced testing solutions that ensure public health and safety. IDEXX's revenue model is supported by recurring sales from consumables associated with its diagnostic instruments, which fosters customer loyalty and ongoing revenue. The company benefits from strategic partnerships with veterinary clinics and animal health organizations, enhancing its market presence and driving sales growth.

Idexx Laboratories Financial Statement Overview

Summary

Idexx Laboratories exhibits strong financial health with robust profitability and efficient cash management. The income statement shows consistent revenue growth and operational efficiency. However, the balance sheet's relatively low equity ratio could pose a risk, despite manageable leverage.

Income Statement

Idexx Laboratories demonstrates strong profitability with a consistent increase in gross profit margin, reaching 61.54% in TTM. The net profit margin has also improved to 24.41%, indicating efficient cost management. Revenue growth is steady, with a 2.69% increase in TTM, showcasing resilience in a competitive industry. EBIT and EBITDA margins are robust, reflecting operational efficiency.

Balance Sheet

The company's balance sheet shows a moderate debt-to-equity ratio of 0.85 in TTM, indicating manageable leverage. Return on equity is impressive at 64.42%, highlighting strong profitability relative to shareholder equity. However, the equity ratio is relatively low, suggesting potential vulnerability to financial instability.

Cash Flow

Operating cash flow remains strong, though there is a slight decline in free cash flow growth at -7.56% in TTM. The operating cash flow to net income ratio is healthy at 0.74, indicating good cash generation relative to earnings. The free cash flow to net income ratio is also solid at 0.85, reflecting efficient cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.04B	3.90B	3.66B	3.37B	3.22B	2.71B
Gross Profit	2.48B	2.38B	2.19B	2.00B	1.89B	1.57B
EBITDA	1.40B	1.28B	1.22B	1.01B	1.04B	793.81M
Net Income	985.66M	887.87M	845.04M	679.09M	744.85M	581.78M
Balance Sheet
Total Assets	3.33B	3.29B	3.26B	2.75B	2.44B	2.29B
Cash, Cash Equivalents and Short-Term Investments	164.59M	288.27M	453.93M	112.55M	144.45M	383.93M
Total Debt	1.24B	986.95M	1.07B	1.47B	1.03B	1.00B
Total Liabilities	1.87B	1.70B	1.78B	2.14B	1.75B	1.66B
Stockholders Equity	1.46B	1.60B	1.48B	608.74M	689.99M	632.09M
Cash Flow
Free Cash Flow	774.34M	798.08M	772.88M	394.15M	636.00M	540.44M
Operating Cash Flow	905.81M	929.00M	906.51M	542.98M	755.55M	648.06M
Investing Cash Flow	-130.45M	-207.06M	-125.25M	-195.35M	-292.97M	-109.38M
Financing Cash Flow	-1.02B	-878.07M	-442.00M	-370.94M	-697.41M	-248.42M

Idexx Laboratories Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 637.34
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDXX, the sentiment is Positive. The current price of 637.34 is above the 20-day moving average (MA) of 632.87, below the 50-day MA of 640.50, and above the 200-day MA of 514.68, indicating a neutral trend. The MACD of -0.23 indicates Negative momentum. The RSI at 52.35 is Neutral, neither overbought nor oversold. The STOCH value of 75.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDXX.

Idexx Laboratories Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
A	79 Outperform	$40.00B	33.09	19.88%	0.70%	4.48%	-11.52%
ZTS	76 Outperform	$63.49B	24.65	52.54%	1.35%	5.27%	13.72%
IDXX	73 Outperform	$50.99B	53.05	64.87%	―	6.68%	18.84%
ELAN	72 Outperform	$10.19B	23.50	6.83%	―	-0.18%	―
RVTY	67 Neutral	$10.91B	39.88	3.61%	0.30%	3.33%	32.86%
ILMN	61 Neutral	$14.29B	11.78	68.11%	―	-3.32%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Idexx Laboratories Corporate Events

IDEXX Laboratories Expands Board with New Director

On July 10, 2025, IDEXX Laboratories announced the election of Joseph L. (Jay) Hooley to its Board of Directors as an independent Class III Director, expanding the board from nine to ten members. Hooley, a former Chair and CEO of State Street Corporation, brings extensive strategic and financial leadership experience, which is expected to enhance the board’s effectiveness. His election reflects IDEXX’s commitment to strengthening its governance as it continues to innovate in the pet healthcare industry.

The most recent analyst rating on (IDXX) stock is a Buy with a $575.00 price target. To see the full list of analyst forecasts on Idexx Laboratories stock, see the IDXX Stock Forecast page.